A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis

Journal of Neurology

Volumn 254, Issue 3, 2007, Pages 306-314

  Soon, Derek ^a   Altmann, Daniel R ^b   Fernando, Kryshani T M ^a   Giovannoni, Garin ^a   Barkhof, Frederick ^c   Polman, Chris H ^c   O'Connor, Paul ^d   Gray, Bruce ^d   Panzara, Michael ^e   Miller, David H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e BIOGEN   (United States)

Author keywords

BBB; MS; Natalizumab; Tysabri

Indexed keywords

GADOLINIUM; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MALE; MEMBRANE DAMAGE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WHITE MATTER;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; STATISTICS, NONPARAMETRIC;

EID: 33947127441     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0356-z     Document Type: Article

References (38)

1. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis, Pathogenetic and clinical implications. Brain 113(Pt 5):1477-1489
2. Adams CW, Poston RN, Buk SJ, Sidhu YS, Vipond H (1985) Inflammatory vasculitis in multiple sclerosis. J Neurol Sci 69:269-283
3. Kirk J, Plumb J, Mirakhur M, McQuaid S (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 201:319-327
4. Kwon EE, Prineas JW (1994) Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions, An immunohistochemical study. J Neuropathol Exp Neurol 53:625-636
5. Claudio L, Raine CS, Brosnan CF (1995) Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis. Acta Neuropathol (Berl) 90:228-238
6. Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH (2001) Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler 7:75-82
7. Plumb J, McQuaid S, Mirakhur M, Kirk J (2002) Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 12:154-169
8. Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ, MacManus DG, Thompson AJ, Miller DH (2000) The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 123(Pt 8):1667-1676
9. Kidd D, Barker GJ, Tofts PS, Gass A, Thompson AJ, McDonald WI, Miller DH (1997) The transverse magnetisation decay characteristics of longstanding lesions and normal-appearing white matter in multiple sclerosis. J Neurol 244:125-130
10. Griffin CM, Dehmeshki J, Chard DT, Parker GJ, Barker GJ, Thompson AJ, Miller DH (2002) T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. Mult Scler 8:211-216
11. Bochner BS, Luscinskas FW, Gimbrone MA Jr, Newman W, Sterbinsky SA, rse-Anthony CP, Klunk D, Schleimer RP (1991) Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 173:1553-1557
12. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR (1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577-584
13. Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, Chi-Rosso G, Newman B, Lobb R (1990) Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 76:965-970
14. Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435
15. Damle NK, Aruffo A (1991) Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+T lymphocytes. Proc Natl Acad Sci USA 88:6403-6407
16. Madri JA, Graesser D, Haas T (1996) The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Biochem Cell Biol 74:749-757
17. Burkly LC, Jakubowski A, Newman BM, Rosa MD, Chi-Rosso G, Lobb RR (1991) Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol 21:2871-2875
18. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63-66
19. Kent SJ, Karlik SJ, Rice GP, Horner HC (1995) A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging 5:535-540
20. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8:3-16
21. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23
22. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, Miller DH (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53:466-472
23. Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, Yang M, Hulme A, O'Connor P, Miller DH (2004) Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 251:407-413
24. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
25. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357-367
26. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, Polman CH, Barkhof F (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50:1282-1288
27. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Ader HJ, Barkhof F (1996) Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476
28. van Walderveen MA, Lycklama ANG, Ader HJ, Jongen PJ, Polman CH, Castelijns JA, Barkhof F (2001) Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 58:76-81
29. Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P (2003) Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 60:1073-1081
30. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den NS, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
31. Studholme C, Hill DLG, Hawkes DJ (1999) An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognit 32:71-86
32. Woods RP, Cherry SR, Mazziotta JC (1992) Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16:620-633
33. Plummer DL (1992) Dispimage: a display and analysis tool for medical images. Rivi Neuroradiol 5:489-495
34. Goldstein H (1995) Multilevel Statistical Models (Kendall's Library of Statistics Series 3). Hodder Arnold
35. Tofts PS, Berkowitz BA (1994) Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methods. Magn Reson Imaging 12:81-91
36. Minagar A, Alexander JS (2003) Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9:540-549
37. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis, Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120(Pt 7):1149-1161
38. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, Martinelli V, Spuler S, Bressi S, Scotti G, Comi G (1996) Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 46:379-384